WO2022257686A1 - 转氨酶、固定化转氨酶及用于制备西他列汀的用途 - Google Patents

转氨酶、固定化转氨酶及用于制备西他列汀的用途 Download PDF

Info

Publication number
WO2022257686A1
WO2022257686A1 PCT/CN2022/092053 CN2022092053W WO2022257686A1 WO 2022257686 A1 WO2022257686 A1 WO 2022257686A1 CN 2022092053 W CN2022092053 W CN 2022092053W WO 2022257686 A1 WO2022257686 A1 WO 2022257686A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
transaminase
immobilized
sitagliptin
resin
Prior art date
Application number
PCT/CN2022/092053
Other languages
English (en)
French (fr)
Inventor
焦琦
黄亚威
田振华
王舒
程占冰
孙传民
Original Assignee
弈柯莱生物科技(上海)股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 弈柯莱生物科技(上海)股份有限公司 filed Critical 弈柯莱生物科技(上海)股份有限公司
Publication of WO2022257686A1 publication Critical patent/WO2022257686A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Definitions

  • the invention belongs to the field of biotechnology, and specifically relates to a transaminase, an immobilized transaminase, and the application of the immobilized transaminase in preparing sitagliptin or its intermediate, and the present invention also relates to a sitagliptin or its intermediate method of preparation.
  • Diabetes mellitus is a metabolic disease that occurs due to changes in insulin secretion, leading to insulin deficiency and weakened action, or decreased insulin activity, or under the combined influence of the two. It is characterized by high blood sugar and accompanied by protein, sugar and fat metabolism. disorder. Diabetes and its complications are the third most harmful to human health after cardiovascular diseases and tumors, becoming an important disease that endangers human health. Among the four types of diabetes, type II diabetes accounts for more than 90%, and is more common in middle-aged and elderly people over 30 years old. The cause of disease is mainly due to the body's insensitivity to insulin.
  • Sitagliptin phosphate is the first dipeptidylase-IV (DPP-4) inhibitor approved by the FDA in 2006 for the treatment of type II diabetes. It has obvious hypoglycemic effect when used alone or in combination with metformin and pioglitazone, and is safe to take, with good tolerance and few adverse reactions.
  • DPP-4 dipeptidylase-IV
  • U.S. Patent No. 8,293,507 discloses that Codexis uses the transaminase obtained by transforming Arthrobacter-derived transaminase to catalyze 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4 ]
  • Triazolo[4,3-a]pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one obtains sitagliptin ((2R )-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-(8H) -base]-1-(2,4,5-trifluorophenyl) butan-2-amine), further phosphorylation of sitagliptin to obtain sitagliptin phosphate.
  • the modified transaminase can convert the substrate 4-oxygen under the conditions of 2g/L ketoamide substrate, 0.5M isopropylamine, 22°C, 5% DMSO, 100 ⁇ M pyridoxal phosphate (PLP) and 20mg/mL transaminase polypeptide.
  • PBP pyridoxal phosphate
  • US9617573 continues to transform SEQ ID NO: 110 in US8293507, and the obtained mutant can be used in 50g/L ketoamide substrate, 1.5M isopropylamine (isopropylamine), 55°C, 50% DMSO (v/v), 1mM pyridoxine Under the condition of aldehyde phosphoric acid, 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4] Conversion of triazolo[4,3-a]pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one to sitagliptin. Wherein the mutant with the best effect (SEQ ID NO:130) has a catalytic conversion rate of 90-95%.
  • transaminase mutants are unstable in 100% organic solvents, so the liquid enzymes are immobilized to obtain immobilized enzymes to improve the stability of the transaminases in organic solvents.
  • SEQ ID NO:110 in US8293507 is fixed on SEPABEADS EXE120 resin, the result shows that the SEPABEADS EXE120 immobilized enzyme of SEQ ID NO:110 can catalyze 100g /L of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-( 8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one substrate to sitagliptin, ee value above 99.9%.
  • reaction solvent is the IPAc (isopropyl acetate) solvent saturated with water
  • IPAc isopropyl acetate
  • WO2019011236A1 reported that 1-morpholine-4-(2,4,5-trifluorophenyl)-1,3-butanedione (also referred to as morpholinodione in the present invention) can be prepared by transaminase catalysis (R )-3-amino-1-morpholine-4-(2,4,5-trifluorophenyl)-1-butanone, and then prepare sitagliptin through multi-step reaction, but liquid enzyme is used in the reaction, In the water solvent system containing a certain amount of DMSO, the substrate concentration is not high, and the liquid enzyme cannot be reused, and the cost is high and the efficiency is low when applied to production.
  • the technical problem to be solved by the present invention is to overcome the relatively poor stability when the transaminase is prepared as an immobilized enzyme in the prior art and then used to catalyze the ketoamide substrate to produce sitagliptin or its intermediate
  • the invention provides a transaminase, an immobilized transaminase and a use thereof for preparing sitagliptin or an intermediate thereof due to defects such as low conversion rate and inability to be reused.
  • the transaminase of the present invention is prepared as an immobilized transaminase, when it is used to catalyze a ketoamide substrate to produce sitagliptin or its intermediate, the conversion rate is high, the stereoselectivity is good, the stability is good, and the reusability rate is improved , The operation is simpler, thereby reducing the production cost, which is beneficial to industrialized production.
  • the present inventors have carried out a lot of research on transaminases in the prior art, and found that when some specific sites are mutated, after the transaminase obtained is immobilized, the stability is higher when it is used to catalyze ketoamide substrates and the conversion The rate is higher, and the cost is lower when it is used for the production of sitagliptin or its intermediate.
  • the first aspect of the present invention provides an immobilized transaminase in the preparation of sitagliptin and/or (R)-3-amino-1-morpholine-4-(2,4,5-tri Use in fluorophenyl)-1-butanone;
  • the immobilized transaminase comprises resin and transaminase, and the amino acid sequence of the transaminase is shown in SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49 or variants thereof; Said variant is that the R mutation at position 241 of the amino acid sequence shown in SEQ ID NO:5 is A, H, N, S, L, T, C or M.
  • the amino acid sequence of the variant is such as SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:37, SEQ ID NO:39, SEQ ID Shown in NO:41 or SEQ ID NO:43.
  • the nucleotide sequence of the transaminase is preferably such as SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:38, Shown in SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48 or SEQ ID NO:50;
  • said transaminase is linked to said resin through covalent bonding.
  • the resin is preferably epoxy resin, preferably HFA.
  • the resin is purchased from Suzhou Huitong Chromatographic Separation and Purification Co., Ltd. HFA resin.
  • the concentration of the transaminase carried on the resin in the immobilized transaminase is 150-300 mg/g (that is, the mass of the transaminase carried on the resin per gram is 150-300 mg), such as 250 mg/g .
  • the use includes using the immobilized transaminase to catalyze the ketoamide substrate in a reaction solvent to obtain the sitagliptin and/or (R)-3-amino-1 in the presence of an amino donor. - the step of morpholine-4-(2,4,5-trifluorophenyl)-1-butanone.
  • the reaction solvent is an aqueous solution of isopropanol, preferably the volume content of water in the aqueous solution of isopropanol (water accounts for the volume ratio of the entire solution) is 2% to 20%, more preferably the prepared reaction
  • the system also includes a transaminase cofactor such as pyridoxal phosphate, and its concentration in the entire reaction system is preferably 0.5-5 mg/mL.
  • the ketoamide substrate is 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3- a] pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one and/or 1-morpholin-4-(2,4,5- Trifluorophenyl)-1,3-butanedione.
  • the 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine -7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one referred to as citadione for short in the present invention
  • the specific structural formula is as follows:
  • the specific structural formula of the 1-morpholine-4-(2,4,5-trifluorophenyl)-1,3-butanedione (also referred to as morpholinodione in the present invention) is as follows :
  • the amino donor is isopropylamine.
  • the molar ratio of the amino donor to the ketoamide substrate is 1:1 ⁇ 5:1.
  • the concentration of the ketoamide substrate in the entire reaction system is 20-200 g/L.
  • the mass ratio of the immobilized transaminase to the ketoamide substrate is 1:1-6:1, such as 3:1, 2.5:1 or 2:1.
  • reaction temperature is 30-60°C, preferably 45°C.
  • the second aspect of the present invention provides a kind of immobilized transaminase, and it comprises resin and transaminase, the aminoacid sequence of described transaminase is as SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:47, Shown in SEQ ID NO: 49 or its variant;
  • the variant is that the R mutation at position 241 of the amino acid sequence shown in SEQ ID NO: 5 is A, H, N, S, L, T, C or M.
  • the amino acid sequence of the variant is such as SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:37, SEQ ID NO:39, SEQ ID Shown in NO:41 or SEQ ID NO:43.
  • the nucleotide sequence of the transaminase is preferably such as SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:38, Shown in SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48 or SEQ ID NO:50.
  • said transaminase is linked to said resin through covalent bonding.
  • the resin is preferably epoxy resin, preferably HFA.
  • the resin is purchased from Suzhou Huitong Chromatographic Separation and Purification Co., Ltd. HFA resin.
  • the concentration of the transaminase carried on the resin in the immobilized transaminase is 150-300 mg/g (that is, the mass of the transaminase carried on the resin per gram is 150-300 mg), such as 250 mg/g .
  • the third aspect of the present invention provides a method for preparing immobilized transaminase, which comprises:
  • transaminase 1) contacting the solution of transaminase with resin to form immobilized transaminase, the amino acid sequence of said transaminase is as shown in SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49 or variants thereof shown; the variant is the 241st R mutation in the amino acid sequence shown in SEQ ID NO: 5 to A, H, N, S, L, T, C or M;
  • the amino acid sequence of the variant is such as SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:37, SEQ ID NO:39, SEQ ID Shown in NO:41 or SEQ ID NO:43;
  • the nucleotide sequence of described transaminase is preferably as SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:22, SEQ ID NO: 26. Shown in SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48 or SEQ ID NO: 50.
  • said transaminase is linked to said resin through covalent bonding.
  • the resin is preferably epoxy resin, preferably HFA.
  • the resin is purchased from Suzhou Huitong Chromatographic Separation and Purification Co., Ltd. HFA resin.
  • the transaminase exists in the form of transaminase sludge, and the mass ratio of the transaminase sludge to the resin is 3:1 ⁇ 1:2, such as 5:4.
  • the reaction temperature is 10-40°C, preferably 20-25°C.
  • the reaction time is 10-30 hours, preferably 20-25 hours.
  • the reaction is carried out under stirring, and the stirring rate is preferably 50-300 rpm, such as 150 or 200 rpm.
  • the preparation method of the immobilized transaminase is as follows: take 5g of transaminase (exist in the form of bacteria sludge for example), add dipotassium hydrogen phosphate-potassium dihydrogen phosphate buffer solution (for example, the volume is 50mL, Concentration: 100mM) Mix and high-pressure homogeneously break the cells, centrifuge to collect the supernatant enzyme solution, add 10g K 2 HPO 4 3H 2 O, 1g KH 2 PO 4 and 0.01g PLP, stir to dissolve, add 4g HFA resin (purchased from Suzhou Huitong Chromatographic Separation and Purification Co., Ltd.) was fixed, fixed on a shaker at 20-25° C. and 200 rpm for 20-25 hours, filtered with suction, washed with deionization, and filtered with suction to obtain the immobilized enzyme.
  • dipotassium hydrogen phosphate-potassium dihydrogen phosphate buffer solution for example, the volume is 50mL,
  • the fourth aspect of the present invention provides a method for preparing sitagliptin and/or (R)-3-amino-1-morpholine-4-(2,4,5-trifluorophenyl) - the method for 1-butanone, which comprises in the presence of an amino donor, using an immobilized transaminase as described in the second aspect of the present invention to catalyze a ketoamide substrate to obtain sitagliptin and/or (R) in a reaction solvent - the step of 3-amino-1-morpholine-4-(2,4,5-trifluorophenyl)-1-butanone.
  • the ketoamide substrate is 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3- a] pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one and/or 1-morpholin-4-(2,4,5- Trifluorophenyl)-1,3-butanedione.
  • the reaction solvent is aqueous isopropanol.
  • the amino donor is isopropylamine.
  • the molar ratio of the amino donor to the ketoamide substrate is 1:1 ⁇ 5:1.
  • the volume content of water is 2% to 20%.
  • the concentration of the ketoamide substrate in the entire reaction system is 20g/L-200g/L.
  • the mass ratio of the immobilized transaminase to the substrate is 1:1-6:1, such as 3:1, 2.5:1 or 2:1.
  • the prepared reaction system also includes a transaminase cofactor such as pyridoxal phosphate, and its concentration in the entire reaction system is preferably 0.5-5 mg/mL.
  • a transaminase cofactor such as pyridoxal phosphate
  • the reaction temperature is 30-60°C, preferably 45°C.
  • the fifth aspect of the present invention provides a transaminase
  • the amino acid sequence of the transaminase is such as SEQ ID NO:5, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49 or its variants shown in the variant; the variant is mutated from R to A, H, N, S, L, T, C or M at position 241 of the amino acid sequence shown in SEQ ID NO:5.
  • amino acid sequence of the variant is such as SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:37, SEQ ID NO:39, SEQ ID Shown in NO:41 or SEQ ID NO:43;
  • the nucleotide sequence of the transaminase is as SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 38, SEQ ID NO: 38, SEQ ID NO: ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48 or SEQ ID NO:50.
  • the sixth aspect of the present invention provides a polynucleotide encoding the transaminase described in the fifth aspect of the present invention.
  • the seventh aspect of the present invention provides a recombinant expression vector, which includes the polynucleotide as described in the sixth aspect of the present invention.
  • the backbone of the recombinant expression vector is plasmid pET21a.
  • the eighth aspect of the present invention provides a transformant, which is introduced into a host with the polynucleotide as described in the sixth aspect of the present invention or the recombinant expression vector as described in the seventh aspect of the present invention.
  • the host is Escherichia coli; preferably Escherichia coli BL21.
  • the ninth aspect of the present invention provides a transaminase as described in the fifth aspect of the present invention in the preparation of sitagliptin and/or (R)-3-amino-1-morpholine-4-( Use in 2,4,5-trifluorophenyl)-1-butanone.
  • the use includes using a transaminase to catalyze a ketoamide substrate in a reaction solvent to obtain the sitagliptin and/or (R)-3-amino-1-morpholine-4 in the presence of an amino donor. - the step of (2,4,5-trifluorophenyl)-1-butanone.
  • the reaction solvent is an aqueous solution of isopropanol, preferably the volume content of water in the aqueous solution of isopropanol (water accounts for the volume ratio of the entire solution) is 2% to 20%, more preferably the prepared reaction
  • the system also includes a transaminase cofactor such as pyridoxal phosphate, and its concentration in the entire reaction system is preferably 0.5-5 mg/mL.
  • the ketoamide substrate is 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3- a] pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one and/or 1-morpholin-4-(2,4,5- Trifluorophenyl)-1,3-butanedione.
  • the amino donor is isopropylamine.
  • the molar ratio of the amino donor to the ketoamide substrate is 1:1 ⁇ 5:1.
  • the concentration of the ketoamide substrate in the entire reaction system is 20-200 g/L.
  • the mass ratio of the transaminase to the ketoamide substrate is 1:1-6:1, such as 3:1, 2.5:1 or 2:1.
  • the transaminase exists in the form of immobilized transaminase.
  • the prepared reaction system also includes a transaminase cofactor such as pyridoxal phosphate, and its concentration in the entire reaction system is preferably 0.5-5 mg/mL.
  • a transaminase cofactor such as pyridoxal phosphate
  • reaction temperature is 30-60°C, preferably 45°C.
  • the amount of isopropanol in the isopropanol aqueous solution can completely dissolve the substrate.
  • the volume content of water in the isopropanol aqueous solution (water accounts for the volume ratio of the entire solution) can be 2% to 20%. Too little water will cause the immobilized enzyme to be inactivated, and too much water will result in incomplete dissolution of the substrate.
  • a certain aspect of the present invention also provides a kind of preparation method of sitagliptin phosphate, described preparation method comprises the following steps:
  • step (2) react the (R)-3-amino-1-morpholine-4-(2,4,5-trifluorophenyl)-1-butanone prepared in step (1) to obtain sitagret Tin phosphate.
  • the sitagliptin phosphate is sitagliptin phosphate monohydrate.
  • a certain aspect of the present invention also provides an enzyme preparation, which includes the immobilized transaminase as described in the second aspect of the present invention or the transaminase as described in the fifth aspect of the present invention;
  • the enzyme preparation also includes a transaminase cofactor such as pyridoxal phosphate.
  • a transaminase cofactor such as pyridoxal phosphate.
  • the enzyme preparation can usually be an enzyme preparation obtained from a transaminase-containing transformant host cell obtained in culture or its culture fluid, or a product obtained by processing it; wherein the product refers to An extract obtained from a transformant host cell, an isolated product obtained by isolating or purifying transaminase in the extract, or an immobilized product obtained by immobilizing a transformed cell and its extract or an isolated product of the extract.
  • the reagents and raw materials used in the present invention are all commercially available.
  • the positive and progressive effect of the present invention lies in: after the transaminase of the present invention is prepared as an immobilized transaminase, it is used to catalyze a ketoamide substrate to produce a sitagliptin intermediate with high conversion rate, good stereoselectivity and good stability , The reusable rate is improved, the operation is simpler, and the production cost is reduced, which is beneficial to industrial production.
  • codons corresponding to the amino acids are also conventional in the art, and the corresponding relationship between specific amino acids and codons is shown in Table 2.
  • Pet21a was purchased from Novagen; NdeI enzyme and HindIII enzyme were purchased from Thermo Fisher; BL21 competent cells were purchased from Beijing Dingguochangsheng Biotechnology Co., Ltd.
  • Morpholindione reference substance retention time 27.820min; (R)-3-amino-1-morpholine-4-(2,4,5-trifluorophenyl)-1-butanone retention time: 14.856 min;
  • Sitagliptin reference substance purchased from Beijing Yingxiang Technology Co., Ltd.
  • retention time 17.705min.
  • the raw material of morpholinodione substrate and the reference substance (R)-3-amino-1-morpholine-4-(2,4,5-trifluorophenyl)-1-butanone were synthesized by our company.
  • the method refers to WO2019011236A1; 3-amino-1-morpholine-4-(2,4,5-trifluorophenyl)-1-butanone racemate is synthesized by the laboratory itself, and aminated by morpholinodione and Prepared by catalytic hydrogenation.
  • the raw material of sitagliptin substrate is synthesized by our laboratory, and the synthetic method refers to CN100430397C.
  • the racemate of sitagliptin is synthesized by our laboratory, which is obtained by amination and catalytic hydrogenation of sitagliptin.
  • Chiral HPLC method detects product ee value method as follows:
  • sitagliptin reference substance 17.665min.
  • Enz.1 SEQ ID NO:1, namely the SEQ ID NO:110 in US8293507
  • Enz.2 SEQ ID NO:3, namely the SEQ ID NO:130 in US9617573
  • the gene is synthesized, the restriction site NdeI, HindIII, the vector pET21a.
  • the gene synthesis company is Suzhou Jinweizhi Biotechnology Co., Ltd. (Floor C3, Bio-Nano Technology Park, No. 218, Xinghu Street, Suzhou Industrial Park).
  • the synthetic transaminase gene is transformed into host Escherichia coli BL21 competent cells to obtain engineering strains containing transaminase Enz.1 and Enz.2 genes.
  • transaminases Enz.3-Enz.25 engineered in Table 3, restriction sites NdeI and HindIII, and vector pET21a were used.
  • the synthetic transaminase gene was transformed into host Escherichia coli BL21 competent cells to obtain engineering bacteria Enz.3-Enz.25 containing the transaminase gene in Table 3.
  • transaminase mutant sludge Take 5g of transaminase mutant sludge, add 50mL of 100mM dipotassium hydrogen phosphate-potassium dihydrogen phosphate buffer solution, mix evenly and homogeneously break the cells under high pressure, collect the supernatant enzyme solution by centrifugation, add 10g K 2 HPO 4 3H 2 O, 1g KH 2 PO 4 and 0.01g PLP, stir to dissolve, add 4g HFA resin (purchased from Suzhou Huitong Chromatographic Separation and Purification Co., Ltd.) was fixed, fixed on a shaker at 20-25° C. and 200 rpm for 20-25 hours, filtered with suction, washed with deionization, and filtered with suction to obtain the immobilized enzyme.
  • 4g HFA resin purchased from Suzhou Huitong Chromatographic Separation and Purification Co., Ltd.
  • Example 3 The immobilized enzyme of each transaminase mutant is used to catalyze morpholinodione
  • the method for detecting the conversion rate by HPLC refers to the above-mentioned conversion rate HPLC method part. After testing, it was found that the retention times of each substrate and product were consistent with their respective reference substances.
  • the immobilized enzyme was applied repeatedly according to the above method, and the result showed that the conversion rate of the immobilized enzyme remained above 90% and the ee value was >99.9%, and the immobilized enzyme was relatively stable.
  • Enz.1 and Enz.2 were applied mechanically three times under the same conditions, and the conversion rates were all below 50%, so they were not suitable for catalyzing morpholinodione.
  • the specific application results are shown in Table 5 below.
  • Embodiment 5 The immobilized enzyme of each transaminase mutant is used to catalyze sitadione
  • the method for detecting the conversion rate by HPLC refers to the above-mentioned conversion rate HPLC method part. After testing, the retention times of each substrate and product were consistent with their respective reference substances.
  • the protein concentration of these better immobilized enzymes was measured.
  • the detection method the change of the absorbance value of the enzyme solution at 595nm before and after immobilization was detected by the Bradford method, and then the protein concentration was calculated. The measurement results are shown in Table 7 below:
  • Example 6 After the reaction in Example 6 was completed, it was filtered to obtain the immobilized enzyme and the filtrate, and the filtrate was concentrated and dried at 60° C. to obtain the concentrate.
  • Add 100mL of dichloromethane to dissolve add 100mL of purified water, stir, use 30% concentrated hydrochloric acid to adjust the pH to between 2-3, and let stand to separate layers.
  • Add 100 mL of dichloromethane to the aqueous phase stir, add 30% sodium hydroxide solution to adjust the pH to 11, and let stand to separate layers.
  • 100 mL of dichloromethane was added to the aqueous phase again, stirred and extracted, and the layers were separated after standing. The organic phases of the two basic extractions were combined.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

提供了一种固定化转氨酶在制备西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮中的用途；所述固定化转氨酶包括树脂和转氨酶，所述转氨酶的氨基酸序列如SEQ ID NO:5、SEQ ID NO:45、SEQ ID NO:47、SEQ ID NO:49或其变体所示；所述变体为在如SEQ ID NO:5所示氨基酸序列的第241位的R突变为A、H、N、S、L、T、C或M。还提供了一种固定化转氨酶、一种转氨酶及其制备方法和用途。

Description

转氨酶、固定化转氨酶及用于制备西他列汀的用途
本申请要求申请日为2021/6/11的中国专利申请2021106553499的优先权。本申请引用上述中国专利申请的全文。
技术领域
本发明属于生物技术领域，具体涉及一种转氨酶、固定化转氨酶，以及该固定化转氨酶在制备西他列汀或其中间体中的应用，本发明还涉及一种西他列汀或其中间体的制备方法。
背景技术
糖尿病是由于胰岛素分泌改变，导致胰岛素缺乏及作用减弱，或者胰岛素活性降低，或者在两者共同影响下，出现的代谢性疾病，以高血糖为特征，并同时伴有蛋白质、糖及脂肪的代谢紊乱。糖尿病及其并发症对人类健康的危害程度居心血管疾病、肿瘤之后的第三位，成为危害人类健康的重要疾病。在糖尿病的四种类型中，II型糖尿病占90％以上，多见于30岁以上的中老年人，病因主要是由于机体对胰岛素不敏感。
西他列汀磷酸盐(Sitagliptin phosphate)是2006年FDA批准上市的第一个二肽基酶-IV(DPP-4)抑制剂，用于治疗II型糖尿病。其单用或与二甲双胍、吡格列酮合用都有明显的降血糖作用，且服用安全，耐受性好，不良反应少。
美国专利US8293507公开了Codexis公司用对节杆菌来源的转氨酶进行改造得到的转氨酶催化4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮得到西他列汀((2R)-4-氧-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-胺)，西他列汀进一步磷酸化得到西他列汀磷酸盐。经改造的转氨酶能够在2g/L酮酰胺底物，0.5M异丙胺，22℃，5％DMSO，100μM吡哆醛磷酸(PLP)和20mg/mL转氨酶多肽的条件下，将底物4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮(在本申请中简称为西他双酮)转化成西他列汀到HPLC-UV在210nm可检测的水平。其中效果最好的突变体(SEQ ID NO:110)的催化转化率可达90-95％。
Figure PCTCN2022092053-appb-000001
US9617573继续对US8293507中SEQ ID NO:110进行改造，所获突变体能够在50g/L酮酰胺底物，1.5M异丙胺(isopropylamine)，55℃，50％DMSO(v/v)，1mM吡哆醛磷酸的条件下，以至少1.2倍于SEQ ID NO:110的活性将4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮转化成西他列汀。其中效果最好的突变体(SEQ ID NO:130)的催化转化率可达90-95％。
但是这些转氨酶突变体在100％有机溶剂中都是不稳定的，因此将液体酶进行固定，得到固定化酶，以提高转氨酶在有机溶剂中的稳定性。如US9587229公开了将US8293507中的SEQ ID NO:110固定在SEPABEADS EXE120树脂上，结果显示SEQ ID NO:110的SEPABEADS EXE120固定化酶在水饱和的IPAc(乙酸异丙酯)溶剂中，能催化100g/L的4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮的底物至西他列汀，ee值99.9％以上。但是US9587229中并没有研究固定化酶的可重复使用率(套用批次数)，且反应溶剂为水饱和的IPAc(乙酸异丙酯)溶剂，采用此溶剂用于生产时，需要事先将IPAc进行水饱和，操作更繁琐，如果用于多批次套用反应，其反应体系中含水量也不好控制，影响固定化酶的水活度，使固定化酶容易失活变性。
WO2019011236A1报道了1-吗啉-4-(2,4,5-三氟苯基)-1,3-丁二酮(本发明中又简称为吗啉双酮)可以经转氨酶催化制得(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮，再经多步反应制得西他列汀，但是反应中采用液体酶，含一定量的DMSO的水溶剂体系，底物浓度不高，液体酶不能重复利用，应用于生产时成本较高、效率较低。
Figure PCTCN2022092053-appb-000002
发明内容
本发明所要解决的技术问题是为了克服现有技术中将转氨酶制备成固定化酶时用于反应体系时稳定性仍然较差进而用于催化酮酰胺底物以生产西他列汀或其中间体时转化率不高、不能重复利用等缺陷，提供了一种转氨酶、固定化转氨酶及其用于制备西他列 汀或其中间体的用途。将本发明的转氨酶制备成固定化转氨酶后，将其用于催化酮酰胺底物以生产西他列汀或其中间体时转化率高且立体选择性好、稳定性好、可重复使用率提高、操作更简单，进而降低了生产成本，有利于工业化生产。
本发明人对现有技术中的转氨酶进行了大量研究，发现进行某些具体位点发生突变时，所得的转氨酶进行固定化后，将其用于催化酮酰胺底物时稳定性更高且转化率更高，将其用于西他列汀或其中间体的生产时成本更低。
为了解决上述技术问题，本发明第一方面提供了一种固定化转氨酶在制备西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮中的用途；
其中，所述固定化转氨酶包括树脂和转氨酶，所述转氨酶的氨基酸序列如SEQ ID NO:5、SEQ ID NO:45、SEQ ID NO:47、SEQ ID NO:49或其变体所示；所述变体为在如SEQ ID NO:5所示氨基酸序列的第241位的R突变为A、H、N、S、L、T、C或M。
较佳地，所述变体的氨基酸序列如SEQ ID NO:11、SEQ ID NO:15、SEQ ID NO:21、SEQ ID NO:25、SEQ ID NO:37、SEQ ID NO:39、SEQ ID NO:41或SEQ ID NO:43所示。更佳地，所述转氨酶的核苷酸序列优选如SEQ ID NO:6、SEQ ID NO:12、SEQ ID NO:16、SEQ ID NO:22、SEQ ID NO:26、SEQ ID NO:38、SEQ ID NO:40、SEQ ID NO:42、SEQ ID NO:44、SEQ ID NO:46、SEQ ID NO:48或SEQ ID NO:50所示；
较佳地，所述的转氨酶与所述树脂通过共价键合作用连接。
较佳地，所述的树脂优选为环氧树脂，优选
Figure PCTCN2022092053-appb-000003
HFA。在某一较佳实施例中，所述的树脂为采购于苏州汇通色谱分离纯化有限公司的
Figure PCTCN2022092053-appb-000004
HFA树脂。
较佳地，所述固定化转氨酶中所述树脂上挂载的转氨酶浓度为150～300mg/g(即，每克所述树脂上挂载的转氨酶的质量为150～300mg)，例如250mg/g。
较佳地，所述用途包括在氨基供体存在时，在反应溶剂中用所述的固定化转氨酶催化酮酰胺底物得所述西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮的步骤。
更佳地，所述的反应溶剂为异丙醇水溶液，优选所述异丙醇水溶液中水的体积含量(水占整个溶液的体积比)为2％～20％，更优选所述制备的反应体系中还包括转氨酶的辅助因子例如吡哆醛磷酸，其占整个反应体系的浓度优选为0.5～5mg/mL。
更佳地，所述酮酰胺底物为4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮和/或1-吗啉-4-(2,4,5-三氟苯基)-1,3-丁二酮。
本发明中，所述的4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮(本发明中又简称为西他双酮)，具体结构式如下：
Figure PCTCN2022092053-appb-000005
本发明中，所述的1-吗啉-4-(2,4,5-三氟苯基)-1,3-丁二酮(本发明中又简称为吗啉双酮)，具体结构式如下：
Figure PCTCN2022092053-appb-000006
更佳地，所述氨基供体为异丙胺。
更佳地，所述氨基供体与所述酮酰胺底物的摩尔比为1:1～5:1。
更佳地，所述酮酰胺底物占整个反应体系的浓度为20～200g/L。
更佳地，所述固定化转氨酶与所述酮酰胺底物的质量比为1:1～6:1，例如3:1，2.5:1或2:1。
更佳地，所述反应的温度为30-60℃，优选45℃。
为了解决上述技术问题，本发明第二方面提供了一种固定化转氨酶，其包括树脂和转氨酶，所述转氨酶的氨基酸序列如SEQ ID NO:5、SEQ ID NO:45、SEQ ID NO:47、SEQ ID NO:49或其变体所示；所述变体为在如SEQ ID NO:5所示氨基酸序列的第241位的R突变为A、H、N、S、L、T、C或M。
较佳地，所述变体的氨基酸序列如SEQ ID NO:11、SEQ ID NO:15、SEQ ID NO:21、SEQ ID NO:25、SEQ ID NO:37、SEQ ID NO:39、SEQ ID NO:41或SEQ ID NO:43所示。更佳地，所述转氨酶的核苷酸序列优选如SEQ ID NO:6、SEQ ID NO:12、SEQ ID NO:16、SEQ ID NO:22、SEQ ID NO:26、SEQ ID NO:38、SEQ ID NO:40、SEQ ID NO:42、SEQ ID NO:44、SEQ ID NO:46、SEQ ID NO:48或SEQ ID NO:50所示。
较佳地，所述的转氨酶与所述树脂通过共价键合作用连接。
较佳地，所述的树脂优选为环氧树脂，优选
Figure PCTCN2022092053-appb-000007
HFA。在某一较佳实施例中，所述的树脂为采购于苏州汇通色谱分离纯化有限公司的
Figure PCTCN2022092053-appb-000008
HFA树脂。
较佳地，所述固定化转氨酶中所述树脂上挂载的转氨酶浓度为150～300mg/g(即，每克所述树脂上挂载的转氨酶的质量为150～300mg)，例如250mg/g。为了解决上述技 术问题，本发明第三方面提供了一种制备固定化转氨酶的方法，其包括：
1)使转氨酶的溶液和树脂接触以形成固定化转氨酶，所述转氨酶的氨基酸序列如SEQ ID NO:5、SEQ ID NO:45、SEQ ID NO:47、SEQ ID NO:49或其变体所示；所述变体为在如SEQ ID NO:5所示氨基酸序列的第241位的R突变为A、H、N、S、L、T、C或M；
2)过滤和冲洗所述固定化转氨酶。
较佳地，所述变体的氨基酸序列如SEQ ID NO:11、SEQ ID NO:15、SEQ ID NO:21、SEQ ID NO:25、SEQ ID NO:37、SEQ ID NO:39、SEQ ID NO:41或SEQ ID NO:43所示；所述转氨酶的核苷酸序列优选如SEQ ID NO:6、SEQ ID NO:12、SEQ ID NO:16、SEQ ID NO:22、SEQ ID NO:26、SEQ ID NO:38、SEQ ID NO:40、SEQ ID NO:42、SEQ ID NO:44、SEQ ID NO:46、SEQ ID NO:48或SEQ ID NO:50所示。
较佳地，所述的转氨酶与所述树脂通过共价键合作用连接。
较佳地，所述的树脂优选为环氧树脂，优选
Figure PCTCN2022092053-appb-000009
HFA。在某一较佳实施例中，所述的树脂为采购于苏州汇通色谱分离纯化有限公司的
Figure PCTCN2022092053-appb-000010
HFA树脂。
较佳地，所述转氨酶以转氨酶菌泥的形式存在，所述转氨酶菌泥与所述树脂的质量比为3:1～1:2，例如5:4。
较佳地，所述反应的温度为10～40℃，优选20～25℃。
较佳地，所述反应的时间为10～30h，优选20～25小时。
较佳地，所述反应在搅拌下进行，所述搅拌的速率优选为50～300rpm，例如150或200rpm。
在某一较佳实施例中，所述固定化转氨酶的制备方法如下：取5g转氨酶(例如以菌泥的形式存在)，加磷酸氢二钾-磷酸二氢钾缓冲液(例如体积为50mL，浓度为100mM)混匀高压均质破碎细胞、离心收集上清液酶液，加入10g K 2HPO 4·3H 2O、1g KH 2PO 4和0.01g PLP，搅拌溶解，加入4g
Figure PCTCN2022092053-appb-000011
HFA树脂(采购于苏州汇通色谱分离纯化有限公司)进行固定，20～25℃、200rpm摇床固定20～25h，抽滤，去离子洗涤，抽滤得到固定化酶。
为了解决上述技术问题，本发明第四方面提供了一种制备西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮的方法，其包括在氨基供体存在时，在反应溶剂中用如本发明第二方面所述的固定化转氨酶催化酮酰胺底物得西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮的步骤。
较佳地，所述酮酰胺底物为4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮和/或1-吗啉-4-(2,4,5-三氟苯基)-1,3-丁二酮。
较佳地，所述反应溶剂为异丙醇水溶液。
较佳地，所述氨基供体为异丙胺。
较佳地，所述氨基供体与所述酮酰胺底物的摩尔比为1:1～5:1。
较佳地，当所述反应溶剂为异丙醇水溶液时，水的体积含量(水占整个溶液的体积比)为2％～20％。
较佳地，所述酮酰胺底物占整个反应体系的浓度为20g/L～200g/L。
较佳地，所述固定化转氨酶与底物的质量比为1:1～6:1，例如3:1，2.5:1或2:1。
较佳地，所述制备的反应体系中还包括转氨酶的辅助因子例如吡哆醛磷酸，其占整个反应体系的浓度优选为0.5～5mg/mL。
较佳地，所述反应的温度为30-60℃，优选45℃。
为了解决上述技术问题，本发明第五方面提供了一种转氨酶，所述转氨酶的氨基酸序列如SEQ ID NO:5、SEQ ID NO:45、SEQ ID NO:47、SEQ ID NO:49或其变体所示；所述变体为在如SEQ ID NO:5所示的氨基酸序列的第241位由R突变为A、H、N、S、L、T、C或M。
较佳地，所述变体的氨基酸序列如SEQ ID NO:11、SEQ ID NO:15、SEQ ID NO:21、SEQ ID NO:25、SEQ ID NO:37、SEQ ID NO:39、SEQ ID NO:41或SEQ ID NO:43所示；
更佳地，所述转氨酶的核苷酸序列如SEQ ID NO:6、SEQ ID NO:12、SEQ ID NO:16、SEQ ID NO:22、SEQ ID NO:26、SEQ ID NO:38、SEQ ID NO:40、SEQ ID NO:42、SEQ ID NO:44、SEQ ID NO:46、SEQ ID NO:48或SEQ ID NO:50所示。
为了解决上述技术问题，本发明第六方面提供了一种多核苷酸，其编码如本发明第五方面所述的转氨酶。
为了解决上述技术问题，本发明第七方面提供了一种重组表达载体，其包括如本发明第六方面所述的多核苷酸。
较佳地，所述重组表达载体的骨架为质粒pET21a。
为了解决上述技术问题，本发明第八方面提供了一种转化体，其为在宿主中导入如本发明第六方面所述的多核苷酸或者如本发明第七方面所述的重组表达载体。
较佳地，所述宿主为大肠杆菌；优选大肠杆菌BL21。
为了解决上述技术问题，本发明第九方面提供了一种如本发明第五方面所述的转氨 酶在制备西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮中的用途。
较佳地，所述用途包括在氨基供体存在时，在反应溶剂中用转氨酶催化酮酰胺底物得所述西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮的步骤。
更佳地，所述的反应溶剂为异丙醇水溶液，优选所述异丙醇水溶液中水的体积含量(水占整个溶液的体积比)为2％～20％，更优选所述制备的反应体系中还包括转氨酶的辅助因子例如吡哆醛磷酸，其占整个反应体系的浓度优选为0.5～5mg/mL。
更佳地，所述酮酰胺底物为4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮和/或1-吗啉-4-(2,4,5-三氟苯基)-1,3-丁二酮。
更佳地，所述氨基供体为异丙胺。
更佳地，所述氨基供体与所述酮酰胺底物的摩尔比为1:1～5:1。
更佳地，所述酮酰胺底物占整个反应体系的浓度为20～200g/L。
更佳地，所述转氨酶与所述酮酰胺底物的质量比为1:1～6:1，例如3:1，2.5:1或2:1。
更佳地，所述转氨酶以固定化的转氨酶的形式存在。
更佳地，所述制备的反应体系中还包括转氨酶的辅助因子例如吡哆醛磷酸，其占整个反应体系的浓度优选为0.5～5mg/mL。
更佳地，所述反应的温度为30-60℃，优选45℃。
本发明中，所述异丙醇水溶液中异丙醇的量能让底物全部溶解即可。异丙醇水溶液中水的体积含量(水占整个溶液的体积比)可以为2％～20％，水太少会让固定化酶失活，水太多则底物溶解不彻底。
本发明某一方面还提供了一种西他列汀磷酸盐的制备方法，所述制备方法包括下述步骤：
(1)按照如本发明第四方面所述的制备方法，制得西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮；
(2)将步骤(1)制得的(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮进行反应，得到西他列汀磷酸盐。
较佳地，所述西他列汀磷酸盐为西他列汀磷酸盐一水合物。
本发明某一方面还提供了一种酶制剂，其包括如本发明第二方面所述的固定化转氨酶或如本发明第五方面所述的转氨酶；
较佳地，所述酶制剂还包括转氨酶的辅助因子例如吡哆醛磷酸。
本发明中，所述的酶制剂通常可以是从培养物中获得的含转氨酶的转化体宿主细胞或其培养液得到的酶制剂，或者用其加工后得到的制品；其中，所述制品是指由转化体 宿主细胞得到的提取物，通过对提取物中的转氨酶进行分离或纯化得到的分离产品，或通过固定化转化体细胞及其提取物或提取物的分离产品而得到的固定化制品。
在符合本领域常识的基础上，上述各优选条件，可任意组合，即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于：将本发明的转氨酶制备成固定化转氨酶后，将其用于催化酮酰胺底物以生产西他列汀中间体时转化率高且立体选择性好、稳定性好、可重复使用率提高、操作更简单，进而降低了生产成本，有利于工业化生产。
具体实施方式
下面通过实施例的方式进一步说明本发明，但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法，按照常规方法和条件，或按照商品说明书选择。
本发明中的实验方法如无特别说明均为常规方法，基因克隆操作具体可参加J.萨姆布鲁克等编的《分子克隆实验指南》。
本发明中的氨基酸简写符号如无特殊说明均为本领域常规，具体简写符号对应的氨基酸如表1所示。
表1
Figure PCTCN2022092053-appb-000012
Figure PCTCN2022092053-appb-000013
所述氨基酸对应的密码子也为本领域常规，具体氨基酸与密码子的对应关系如表2所示。
表2
Figure PCTCN2022092053-appb-000014
Pet21a购买自Novagen公司；NdeI酶、HindIII酶购买自Thermo Fisher公司，BL21感受态细胞购买自北京鼎国昌盛生物技术有限责任公司。
转化率HPLC方法：色谱柱：C18柱4.6×250mm，5μm；检测器：UV268nm；柱温：40℃；流速：0.8mL/min；进样量：20μL；流动相A：水:乙腈:甲酸:氨水＝950:50:0.5:0.5，pH应在3.60～3.80之间，如果pH达不到，10％的氨水或者10％的甲酸调整pH到3.70； 也可使用甲酸铵调节pH到3.70；流动相B：水:乙腈＝20:80；梯度洗脱：100％A(0.01min)，60％A+40％B(20min)，60％A+40％B(40min)，100％A(50min)，100％A(60min)。
吗啉双酮对照品保留时间：27.820min；(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮对照品保留时间：14.856min；
西他双酮对照品保留时间：34.715min；
西他列汀对照品(采购于北京盈祥科技有限公司)保留时间：17.705min。
其中，吗啉双酮底物原料和对照品(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮由本公司自行合成，合成方法参考WO2019011236A1；3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮消旋体由实验室自行合成，由吗啉双酮进行氨基化和催化加氢制得。对照品(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮构型的确定：(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮可进一步反应制得(3R)-N-叔丁氧羰基-3-氨基-4-(2,4,5-三氟苯基)-丁酸(参考WO2019011236A1)，以采购于安徽海康药业有限责任公司(3R)-N-叔丁氧羰基-3-氨基-4-(2,4,5-三氟苯基)-丁酸标准品做对照，可以确定为R构型。
构型确定的HPLC方法：
色谱柱：Daicel Chiralpak AD-H(4.6mm*250mm,5μm)；流动相：正己烷：异丙醇＝90:10；检测波长：210nm；流速：1.0ml/min；进样体积：10μl；柱温：25℃；运行时间：40min。
西他双酮底物原料由本实验室自行合成，合成方法参考CN100430397C，西他列汀消旋体由本实验室自行合成，由西他双酮进行氨基化和催化加氢制得。
手性HPLC方法检测产物ee值方法如下：
色谱柱：Daicel ChiralpakAD-H柱4.6mm×250mm，5μm；流动相：正己烷:异丙醇:二乙胺＝40:60:0.1；检测器：UV268nm；柱温：25℃；流速：0.8mL/min；进样量：10μL。
3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮消旋体对照品保留时间：10.290min和28.087min；
(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮对照品保留时间：28.093min。
西他列汀消旋体对照品保留时间：14.172min和17.702min；
西他列汀对照品保留时间：17.665min。
实施例1 一种转氨酶突变体酶液的制备
根据已报道的Enz.1(SEQ ID NO:1，即US8293507中的SEQ ID NO:110)、Enz.2 (SEQ ID NO:3，即US9617573中的SEQ ID NO:130)的编码基因，全基因进行合成，酶切位点NdeI、HindIII，载体pET21a。基因合成公司为苏州金唯智生物科技有限公司(苏州工业园区星湖街218号生物纳米科技园C3楼)。合成的转氨酶基因转化至宿主大肠杆菌BL21感受态细胞，得到含有转氨酶Enz.1、Enz.2基因的工程菌株。
同样地，将表3中工程化得到的转氨酶Enz.3～Enz.25的基因，酶切位点NdeI、HindIII，载体pET21a。合成的转氨酶基因转化至宿主大肠杆菌BL21感受态细胞，得到表3含有转氨酶基因的工程菌Enz.3～Enz.25。
表3
Figure PCTCN2022092053-appb-000015
Figure PCTCN2022092053-appb-000016
将含有转氨酶基因的工程菌在经平皿划线活化后，挑单菌落接种至含50μg/ml卡那霉素的5ml LB液体培养基中，37℃震荡培养12h。按2％(v/v)接种量转接至150ml同样含50μg/ml卡那霉素的新鲜LB液体培养基中，37℃震荡至OD600达到0.8左右时，加入IPTG至其终浓度为0.5mM，18℃诱导培养16h。培养结束后，将培养液10,000rpm离心10min，弃上清液，收集菌体，置于-80℃超低温冰箱中保存，待用。
实施例2 固定化转氨酶突变体的制备
取5g转氨酶突变体菌泥，加50mL 100mM磷酸氢二钾-磷酸二氢钾缓冲液混匀高压均质破碎细胞、离心收集上清液酶液，加入10g K 2HPO 4·3H 2O、1g KH 2PO 4和0.01g PLP，搅拌溶解，加入4g
Figure PCTCN2022092053-appb-000017
HFA树脂(采购于苏州汇通色谱分离纯化有限公司)进行固定，20～25℃、200rpm摇床固定20～25h，抽滤，去离子洗涤，抽滤得到固定化酶。
实施例3 各转氨酶突变体的固定化酶用于催化吗啉双酮
三角瓶中，加入10mL异丙醇，0.5g吗啉双酮，0.8mL 16mg/mL的PLP水溶液，0.25mL异丙胺和1g实施例2中制得的固定化酶，45℃、200rpm摇床反应，反应4小时和24小时取样检测转化率。检测结果如下表4所示。
其中，HPLC检测转化率的方法见上述的转化率HPLC方法部分。经过检测发现，各底物和产物的保留时间与各自的对照品一致。
表4
Figure PCTCN2022092053-appb-000018
Figure PCTCN2022092053-appb-000019
结果显示Enz.3、Enz.6、Enz.8、Enz.11、Enz.13、Enz.19、Enz.20、Enz.21、Enz.22、Enz.23、Enz.24、Enz.25的转化率都优于Enz.2和Enz.1，其中Enz.6、Enz.11、Enz.24的24小时的转化率均可达到80％以上。
实施例4 固定化酶
Figure PCTCN2022092053-appb-000020
HFA多批次催化吗啉双酮
三角瓶中，加入25mL异丙醇，2.5g吗啉双酮，2mL 16mg/mL的PLP水溶液，1.24mL异丙胺和7.5g实施例2中制得的固定化酶，45℃、200rpm摇床反应，反应24小时取样检测转化率。过滤反应液得固定化酶，继续加入25mL异丙醇，2.5g吗啉双酮，2mL 16mg/mL的PLP水溶液，1.24mL异丙胺，45℃、200rpm摇床反应，反应24小时 取样检测转化率。按照上述方法固定化酶重复套用，结果显示固定化酶套用10批反应，转化率仍然保持在90％以上，ee值>99.9％，固定化酶比较稳定。而Enz.1和Enz.2在同样条件下套用3次的转化率都在50％以下，不适合用来催化吗啉双酮。具体套用结果见下表5。
表5
Figure PCTCN2022092053-appb-000021
实施例5 各转氨酶突变体的固定化酶用于催化西他双酮
三角瓶中，加入10mL异丙醇，0.5g西他双酮，0.8mL 16mg/mL的PLP水溶液，0.23mL异丙胺和1g实施例2中制得的固定化酶，45℃、200rpm摇床反应，反应4小时和24小时取样HPLC检测转化率，检测结果如下表6所示。
其中，HPLC检测转化率的方法见上述的转化率HPLC方法部分。经检测，各底物和产物的保留时间与各自的对照品一致。
表6
Figure PCTCN2022092053-appb-000022
Figure PCTCN2022092053-appb-000023
结果显示，Enz.3、Enz.6、Enz.11、Enz.13、Enz.19、Enz.20、Enz.21、Enz.22的转化率都优于Enz.1和Enz.2，其中Enz.11的效果最优。
将这些较好的固定化酶进行蛋白浓度测定，检测方法：采用Bradford法检测固定化前后酶液在595nm处吸光值变化，进而计算出蛋白浓度，测定结果如下表7所示：
表7
Figure PCTCN2022092053-appb-000024
Figure PCTCN2022092053-appb-000025
实施例6 固定化酶
Figure PCTCN2022092053-appb-000026
HFA多批次催化西他双酮
三角瓶中，加入25mL异丙醇，2.5g西他双酮，2mL 16mg/mL的PLP水溶液，1.135mL异丙胺和6.25g实施例2中制得的固定化酶，45℃、200rpm摇床反应，反应24小时取样检测转化率。过滤反应液得固定化酶，继续加入25mL异丙醇，2.5g西他双酮，2mL 16mg/mL的PLP水溶液，1.135mL异丙胺，45℃、200rpm摇床反应，反应24小时取样检测转化率。按照上述方法固定化酶重复套用，结果显示固定化酶
Figure PCTCN2022092053-appb-000027
Figure PCTCN2022092053-appb-000028
HFA套用10批反应，转化率仍然保持在95％以上，ee值>99.9％，固定化酶比较稳定。具体套用结果见下表8。
表8
Figure PCTCN2022092053-appb-000029
*：与Enz.1的转化率比较；#：与Enz.2的转化率比较
以上结果说明，本发明的转氨酶突变在固定化酶催化西他双酮的实验中，显示了比现有技术Enz.1和Enz.2用于固定化酶催化时转化率更优异的效果，且该差异有统计学意义(p值均小于0.001，其中p值的计算是用T-Test双尾实验)。
实施例7 西他列汀磷酸盐一水合物的制备
待实施例6反应结束后，过滤，得到固定化酶和滤液，滤液60℃下浓缩拉干得到浓缩物。加入100mL二氯甲烷溶解，加入100mL纯化水，搅拌，用30％浓盐酸调pH至2-3之间，静置分层。水相加入100mL二氯甲烷，搅拌，加入30％氢氧化钠溶液调pH至11，静置分层。水相再次加入100mL二氯甲烷，搅拌萃取，静置分层。合并两次碱萃的有机相。60℃浓缩，浓缩物加入120mL异丙醇，搅拌溶解，加入10.6g的85％磷酸，升温至75℃，搅拌溶清，缓慢降温使西他列汀磷酸盐结晶析出，5℃保温2h，过滤，滤饼放于60℃烘干干燥，得到西他列汀磷酸盐一水合物。

Claims (11)

  1. 一种固定化转氨酶在制备西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮中的用途；
    其中，所述固定化转氨酶包括树脂和转氨酶，所述转氨酶的氨基酸序列如SEQ ID NO:5、SEQ ID NO:45、SEQ ID NO:47、SEQ ID NO:49或其变体所示；所述变体为在如SEQ ID NO:5所示氨基酸序列的第241位的R突变为A、H、N、S、L、T、C或M；
    较佳地：
    所述变体的氨基酸序列如SEQ ID NO:11、SEQ ID NO:15、SEQ ID NO:21、SEQ ID NO:25、SEQ ID NO:37、SEQ ID NO:39、SEQ ID NO:41或SEQ ID NO:43所示；所述转氨酶的核苷酸序列优选如SEQ ID NO:6、SEQ ID NO:12、SEQ ID NO:16、SEQ ID NO:22、SEQ ID NO:26、SEQ ID NO:38、SEQ ID NO:40、SEQ ID NO:42、SEQ ID NO:44、SEQ ID NO:46、SEQ ID NO:48或SEQ ID NO:50所示；和/或，所述的转氨酶与所述树脂通过共价键合作用连接；和/或，所述的树脂为环氧树脂，优选为
    Figure PCTCN2022092053-appb-100001
    和/或，所述的制备中使用的反应溶剂为异丙醇水溶液，优选所述异丙醇水溶液中水的体积含量为2％～20％；和/或，所述制备的反应体系还包括转氨酶的辅助因子例如吡哆醛磷酸，其浓度优选为0.5～5mg/mL；和/或，所述固定化转氨酶中所述树脂上挂载的转氨酶浓度为150～300mg/g，例如250mg/g。
  2. 一种固定化转氨酶，其特征在于，其包括树脂和转氨酶，所述转氨酶的氨基酸序列如SEQ ID NO:5、SEQ ID NO:45、SEQ ID NO:47、SEQ ID NO:49或其变体所示；所述变体为在如SEQ ID NO:5所示氨基酸序列的第241位的R突变为A、H、N、S、L、T、C或M；
    较佳地：
    所述变体的氨基酸序列如SEQ ID NO:11、SEQ ID NO:15、SEQ ID NO:21、SEQ ID NO:25、SEQ ID NO:37、SEQ ID NO:39、SEQ ID NO:41或SEQ ID NO:43所示；所述转氨酶的核苷酸序列优选如SEQ ID NO:6、SEQ ID NO:12、SEQ ID NO:16、SEQ ID NO:22、SEQ ID NO:26、SEQ ID NO:38、SEQ ID NO:40、SEQ ID NO:42、SEQ ID NO:44、SEQ ID NO:46、SEQ ID NO:48或SEQ ID NO:50所示；和/或，所述的转氨酶与所述树脂通过共价键合作用连接；和/或，所述的树脂为环氧树脂，优选为
    Figure PCTCN2022092053-appb-100002
    和/或，所述固定化转氨酶中所述树脂上挂载的转氨酶浓度为150～300mg/g，例如250mg/g。
  3. 一种制备如权利要求2所述的固定化转氨酶的方法，其包括：
    1)使所述转氨酶的溶液和所述树脂接触反应以形成固定化转氨酶；
    2)过滤和冲洗所述固定化转氨酶；
    较佳地：
    所述转氨酶以转氨酶菌泥的形式存在，所述转氨酶菌泥与所述树脂的质量比为3:1～1:2，例如5:4；和/或，所述反应的温度为10～40℃，优选20～25℃；和/或，所述反应的时间为10～30h，优选20～25h；和/或，所述反应在搅拌下进行，所述搅拌的速率优选为50～300rpm，例如150或200rpm。
  4. 一种制备西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮的方法，其包括在氨基供体存在时，在反应溶剂中用固定化转氨酶催化酮酰胺底物得西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮的步骤；
    其中，所述固定化转氨酶如权利要求2所述；
    较佳地，所述酮酰胺底物为4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮和/或1-吗啉-4-(2,4,5-三氟苯基)-1,3-丁二酮；
    和/或，所述反应溶剂为异丙醇水溶液；
    和/或，所述氨基供体为异丙胺；
    和/或，所述氨基供体与所述酮酰胺底物的摩尔比为1:1～5:1；
    和/或，当所述反应溶剂为异丙醇水溶液时，水的体积含量为2％～20％；
    和/或，所述酮酰胺底物的浓度为20～200g/L；
    和/或，所述固定化转氨酶与所述酮酰胺底物的质量比为1:1～6:1，例如3:1，2.5:1或2:1；
    和/或，所述制备的反应体系中还包括转氨酶的辅助因子例如吡哆醛磷酸，其浓度优选为0.5～5mg/mL；
    和/或，所述反应的温度为30-60℃，优选45℃。
  5. 一种转氨酶，其特征在于，所述转氨酶的氨基酸序列如SEQ ID NO:5、SEQ ID NO:45、SEQ ID NO:47、SEQ ID NO:49或其变体所示；所述变体为在如SEQ ID NO:5所示的氨基酸序列的第241位由R突变为A、H、N、S、L、T、C或M；
    较佳地，所述变体的氨基酸序列如SEQ ID NO:11、SEQ ID NO:15、SEQ ID NO:21、SEQ ID NO:25、SEQ ID NO:37、SEQ ID NO:39、SEQ ID NO:41或SEQ ID NO:43所示；
    更佳地，所述转氨酶的核苷酸序列如SEQ ID NO:6、SEQ ID NO:12、SEQ ID NO:16、SEQ ID NO:22、SEQ ID NO:26、SEQ ID NO:38、SEQ ID NO:40、SEQ ID NO:42、 SEQ ID NO:44、SEQ ID NO:46、SEQ ID NO:48或SEQ ID NO:50所示。
  6. 一种多核苷酸，其编码权利要求5所述的转氨酶。
  7. 一种重组表达载体，其包括如权利要求6所述的多核苷酸；
    较佳地，所述重组表达载体的骨架为质粒pET21a。
  8. 一种转化体，其为在宿主中导入如权利要求6所述的多核苷酸或者如权利要求7所述的重组表达载体；
    较佳地，所述宿主为大肠杆菌；优选大肠杆菌BL21。
  9. 一种如权利要求5所述的转氨酶在制备西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮中的用途。
  10. 一种西他列汀磷酸盐的制备方法，其特征在于，所述制备方法包括下述步骤：
    (1)按照权利要求4所述的方法，制得西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮；
    (2)将步骤(1)制得的西他列汀和/或(R)-3-氨基-1-吗啉-4-(2,4,5-三氟苯基)-1-丁酮进行反应，得到西他列汀磷酸盐；
    较佳地，所述西他列汀磷酸盐为西他列汀磷酸盐一水合物。
  11. 一种酶制剂，其包括如权利要求2所述的固定化转氨酶或如权利要求5所述的转氨酶；
    较佳地，所述酶制剂还包括转氨酶的辅助因子例如吡哆醛磷酸。
PCT/CN2022/092053 2021-06-11 2022-05-10 转氨酶、固定化转氨酶及用于制备西他列汀的用途 WO2022257686A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110655349.9A CN115466756A (zh) 2021-06-11 2021-06-11 转氨酶、固定化转氨酶及用于制备西他列汀的用途
CN202110655349.9 2021-06-11

Publications (1)

Publication Number Publication Date
WO2022257686A1 true WO2022257686A1 (zh) 2022-12-15

Family

ID=84364776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/092053 WO2022257686A1 (zh) 2021-06-11 2022-05-10 转氨酶、固定化转氨酶及用于制备西他列汀的用途

Country Status (2)

Country Link
CN (1) CN115466756A (zh)
WO (1) WO2022257686A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116024083A (zh) * 2023-02-22 2023-04-28 凯莱英生命科学技术(天津)有限公司 连续流反应制备手性胺类化合物的装置和方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117467733B (zh) * 2023-12-27 2024-03-12 北京元延医药科技股份有限公司 高手性纯度西格列汀及使用固定化转氨酶制备的方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103608355A (zh) * 2011-06-24 2014-02-26 默沙东公司 固定化转氨酶和生产及使用固定化转氨酶的方法
CN105164263A (zh) * 2013-02-28 2015-12-16 科德克希思公司 用于工业生物催化的工程化转氨酶多肽
CN105219745A (zh) * 2014-06-12 2016-01-06 南京博优康远生物医药科技有限公司 一种固定化转氨酶及其在合成西他列汀中间体中的应用
CN108586346A (zh) * 2018-05-10 2018-09-28 中国国际医药卫生有限公司 一种生物催化合成西他列汀及其中间体的方法
WO2019207443A1 (en) * 2018-04-24 2019-10-31 Unichem Laboratories Ltd An enzymatic process for the preparation of (r)-sitagliptin
WO2020025646A1 (en) * 2018-07-30 2020-02-06 University College Cork - National University Of Ireland, Cork An omega-transaminase enzyme
US20200157109A1 (en) * 2017-07-04 2020-05-21 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid
WO2021077425A1 (zh) * 2019-10-25 2021-04-29 凯莱英医药化学（阜新）技术有限公司 转氨酶突变体及其应用
WO2021135886A1 (zh) * 2019-12-31 2021-07-08 弈柯莱生物科技(上海)股份有限公司 转氨酶突变体、固定化转氨酶及用于制备西他列汀的用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103608355A (zh) * 2011-06-24 2014-02-26 默沙东公司 固定化转氨酶和生产及使用固定化转氨酶的方法
CN105164263A (zh) * 2013-02-28 2015-12-16 科德克希思公司 用于工业生物催化的工程化转氨酶多肽
CN105219745A (zh) * 2014-06-12 2016-01-06 南京博优康远生物医药科技有限公司 一种固定化转氨酶及其在合成西他列汀中间体中的应用
US20200157109A1 (en) * 2017-07-04 2020-05-21 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid
WO2019207443A1 (en) * 2018-04-24 2019-10-31 Unichem Laboratories Ltd An enzymatic process for the preparation of (r)-sitagliptin
CN108586346A (zh) * 2018-05-10 2018-09-28 中国国际医药卫生有限公司 一种生物催化合成西他列汀及其中间体的方法
WO2020025646A1 (en) * 2018-07-30 2020-02-06 University College Cork - National University Of Ireland, Cork An omega-transaminase enzyme
WO2021077425A1 (zh) * 2019-10-25 2021-04-29 凯莱英医药化学（阜新）技术有限公司 转氨酶突变体及其应用
WO2021135886A1 (zh) * 2019-12-31 2021-07-08 弈柯莱生物科技(上海)股份有限公司 转氨酶突变体、固定化转氨酶及用于制备西他列汀的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116024083A (zh) * 2023-02-22 2023-04-28 凯莱英生命科学技术(天津)有限公司 连续流反应制备手性胺类化合物的装置和方法

Also Published As

Publication number Publication date
CN115466756A (zh) 2022-12-13

Similar Documents

Publication Publication Date Title
WO2021135886A1 (zh) 转氨酶突变体、固定化转氨酶及用于制备西他列汀的用途
WO2022257686A1 (zh) 转氨酶、固定化转氨酶及用于制备西他列汀的用途
Senthuran et al. Lactic acid fermentation in a recycle batch reactor using immobilized Lactobacillus casei
Tong et al. Purification of L (+)-lactic acid from fermentation broth with paper sludge as a cellulosic feedstock using weak anion exchanger Amberlite IRA-92
CN101429229B (zh) 一种高纯度谷胱甘肽的生产方法
CN113637713B (zh) 一种制备手性2-氯-3,4-二氟苯乙醇的方法
WO2018023205A1 (zh) 一种烟酰胺单核苷酸的纯化方法
CN112870979B (zh) 一种β-烟酰胺单核苷酸的分离纯化方法
CN109735559B (zh) 一种γ-氨基丁酸的生物制备方法
WO2018107377A1 (zh) 一种nadph的纯化工艺
CN108642113B (zh) 一种高效且稳定制备高f值玉米寡肽的方法
WO2023061237A1 (zh) 转氨酶及其用于制备西他列汀或其中间体的用途
CN111218441B (zh) 磁性固定化酵母细胞及其在制备（r）-2-羟基-4-苯基丁酸乙酯中的应用
WO2020056714A1 (zh) 高纯度核黄素磷酸钠的制备方法
CN108299220A (zh) 一种发酵催化液中提取l-4-羟基异亮氨酸的方法
CN112048485B (zh) 一种制备西他列汀的工程化转氨酶多肽
CN109811019B (zh) 一种制备屈西多巴的方法
CN114028839A (zh) 一种降低产品中苯丙氨酸含量的方法
WO2020107780A1 (zh) 一种化学酶法制备(s)-1，2，3，4-四氢异喹啉-3-甲酸的方法
CN111647634A (zh) 一种填充床连续流不对称合成(S)-1-Boc-3-氨基哌啶的方法
CN111920059A (zh) 一种大豆ace抑制肽及其制备方法和应用
Antony et al. Overview of the Enzyme Support System of Immobilization for Enhanced Efficiency and Reuse of Enzymes
CN101429228A (zh) 一种从谷胱甘肽发酵液中提取分离谷胱甘肽的方法
CN117467733B (zh) 高手性纯度西格列汀及使用固定化转氨酶制备的方法
CN112301067B (zh) 一种制备2-氨基-3-取代苯基-3-羟基丙酸的绿色环保工艺

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22819286

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE